WHO ICTRP trial
Efficacy and safety of Ginkgo Biloba for cognitive function and fatigue in…
ACTRN12610000121066 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12610000121066 |
|---|---|
| Public title | Efficacy and safety of Ginkgo Biloba for cognitive function and fatigue in breast cancer patients after primary adjuvant treatment |
| Scientific title | Efficacy and safety of Ginkgo Biloba for cognitive function and fatigue in breast cancer patients after primary adjuvant treatment |
| Primary sponsor | University of Sydney |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia |
| Conditions | Breast Cancer;Cognitive function; Breast Cancer Cognitive function;Cancer - Breast;Alternative and Complementary Medicine - Herbal remedies;Mental Health - Studies of normal psychology, cognitive function and behaviour |
| Interventions | Ginkgo Biloba (standardised extract EGB 761) encapsulated tablets Dose: 240 mg (2x120 mg) encapsulated tablets taken daily Duration: 6 months |
| Registration date | May 2, 2010 |
| Target size | 72 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: